In a roundup of scientific studies on the novel coronavirus, a small study suggests no traces of mRNA vaccines end up in mothers’ breast milk and a gene called IFI27 that becomes activated early in Covid-19 might help identify people most likely to have contracted the virus after coming in contact with an infected person.
If you are not happy with the results below please do another search
50 search results for:
AB Science announced the publication of long-term follow-up data showing that the company’s lead compound, masitinib, extended survival in Amyotrophic Lateral Sclerosis (ALS) patients by 25 months compared to placebo when treatment was started early.
Genentech’s Hemlibra (emicizumab-kxwh) showed no new safety signals and continued to deliver consistent bleeding control in the final analysis of a long-term, late-stage hemophilia A study.
Germany’s BioNTech is acquiring Kite’s solid tumor neoantigen T-cell receptor (TCR) research-and-development platform and the Gilead company’s clinical manufacturing plant in Gaithersburg, Maryland.
U.S. Surgeon General Vivek Murthy stood by federal guidance that those fully vaccinated against Covid-19 no longer needed to wear masks, while blaming social media companies for fueling vaccine misinformation.
Tokyo Olympics organizers on July 18 reported the first Covid-19 cases among competitors residing in the athletes’ village, as its population swells ahead of the start of the pandemic-hit Games.
Bristol Myers Squibb shared new details on the global biopharmaceutical firm’s Phase III research on a potential first-line treatment for people who have been diagnosed with recurrent or metastatic squamous cell carcinoma of the head and neck.
Facebook on July 17 defended itself against U.S. President Joe Biden’s assertion that the social media platform is “killing people” by allowing misinformation about coronavirus vaccines to proliferate, saying the facts tell a different story.
Regeneron continues to expand the company’s presence in New York. During the next six years, Regeneron will invest $1.8 billion to expand the company’s Tarrytown facilities. The investment will support the addition of 1,000 new jobs.
Boston-based Alexion Pharmaceuticals announced positive topline data from the company’s Phase III trial of Ultomiris (ravulizumab-cwvz) in adults with generalized myasthenia gravis.